Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis

Ya-Wen Zhang, Ling-Lan Tu, Yi Zhang, Jie-Chao Pan, Gao-Li Zheng, and Li-Na Yin

ABSTRACT
Liver fibrosis is a major global health concern. Management of chronic liver disease is severely restricted in clinics due to ineffective treatment approaches. However, a lack of targeted therapy may aggravate this condition. Asiatic acid (AA), a pentacyclic triterpenoid acid, can effectively protect the liver from hepatic disorders. However, the pharmaceutical application of AA is limited by low oral bioavailability and poor targeting efficiency. This study synthesized a novel liver-targeting material from PEG-SA, chemically linked to ursodeoxycholic acid (UA), and utilized it to modify AA nanostructured lipid carriers (UP-AA-NLC) with enhanced targeting and improved efficacy. The formulation of UP-AA-NLC was optimized via the Box–Behnken Experimental Design (BBD) and characterized by size, zeta potential, TEM, DSC, and XRD. Furthermore, in vitro antifibrotic activity and proliferation of AA and NLCs were assessed in LX-2 cells. The addition of UP-AA-NLC significantly stimulated the TGF-beta1-induced expression of α-SMA, FN1, and Col I x1. In vivo near-infrared fluorescence imaging and distribution trials in rats demonstrated that UP-AA-NLC could significantly improve oral absorption and liver-targeting efficiency. Oral UP-AA-NLC greatly alleviated carbon tetrachloride-induced liver injury and fibrosis in rats in a dosage-dependent manner, as reflected by serum biochemical parameters (AST, ALT, and ALB), histopathological features (H&E and Masson staining), and antioxidant activity parameters (SOD and MDA). Also, treatment with UP-AA-NLC lowered liver hydroxyproline levels, demonstrating a reduction of collagen accumulation in the fibrotic liver. Collectively, optimized UP-AA-NLC has potential application prospects in liver-targeted therapy and holds great promise as a drug delivery system for treating liver diseases.

1. Introduction
Liver fibrosis is characterized by excessive deposition of extracellular matrix (ECM) and dysfunction of sinusoidal endothelial cells following chronic liver damage (Shouval & Friedman, 2014). This condition remains a global health problem. If not timely treated, the liver parenchyma is replaced by scar tissue, causing cirrhosis or liver cancer. At present, no anti-fibrosis drugs have been approved. The frequently used drugs in clinics are ineffective due to a lack of organ selectivity and the inability to deliver sufficient drug concentration to the lesion. Additionally, a lack of liver-targeting therapies causes toxicity and side effects. Therefore, it is imperative to develop new drug delivery systems with effective targeting abilities, high accuracy, and low toxicity.

Nanostructured lipid carrier (NLC) is a promising nanotechnology-based drug delivery system that potentially improves in vivo pharmacokinetics and bioavailability of water-insoluble drugs. Compared to traditional lipid carrier delivery systems (such as SLN), the NLC demonstrates better encapsulation and stability as it comprises a mixture of solid–liquid lipids with varying melting points (Müller et al., 2002; Shidhaye et al., 2008). However, the application of NLC in the treatment of liver diseases is limited by low hydrophilicity and lack of active targeting.

Bile acids are endogenous hepatocyte-specific natural ligands, actively transported to hepatocytes via Na+/taurocholate cotransporter (NTCP) on the surface of hepatocytes (Sievanen, 2007). Bile acids can serve as small molecule liver-targeting carriers for oral absorption. Furthermore, bile acids contribute to human hepatocentric circulation and demonstrate a powerful transport capability (Dawson, 2011). Compelling evidence shows that combining bile acids with insoluble drugs can promote liver aggregation and improve oral bioavailability by increasing intestinal membrane permeability and lymphatic transport (Chen et al., 2009, 2010; Zhang et al., 2013; Xiao et al., 2019). Ursodeoxycholic acid (UA), one of the main components of bile acids, is
biocompatible and is absorbed from the intestine into the liver via the active transport pathway after oral administration. Of note, UA has a high transport capacity and organ-specific absorption characteristics, which potentially increase the drug concentration in the liver, prolong circulating time, and reduce side effects (Fiorucci et al., 2001, 2004; Paschke et al., 2003). Studies have also demonstrated the pharmacological activities of UA in protecting the liver (Ye et al., 2020). Therefore, UA can be utilized as a drug carrier and may exert a synergistic role to improve the treatment efficiency of liver diseases.

Traditional Chinese Medicine has excellent advantages in anti-liver fibrosis with its unique view of syndrome differentiation and holistic treatment theory (Zhang & Schuppan, 2014). Asiatic acid (AA) is the main component of Centella asiatica. Evidence indicates that AA can reverse liver fibrosis, relieve liver damage, and has significant hepatoprotective effects (Gao et al., 2006; Pakdeechote et al., 2014). The mechanism of AA in liver fibrosis inhibition is associated with anti-mitochondrial stress, cellular antioxidant, and blocking TGF-β1 autocrine (Mi-Sook et al., 2004; Tang et al., 2012). However, due to the extremely low solubility in water (≤10 μg/mL) and rapid elimination in vivo, the oral bioavailability of AA is extremely low (Chasseaud et al., 1971; Rush et al., 1993). Furthermore, research evidence shows that AA is widely distributed in tissues and organs after administration, showing dose and time dependence, severely limiting its clinical application. In this view, it would be imperative to develop effective liver-targeted drug delivery systems to improve the bioavailability and therapeutic effect of AA. Our previous investigation developed a PEG-modified AA NLC (P- AA-NLC), which passively targeted the liver and improved oral absorption (Chen et al., 2020). Herein, we modified an AA NLC with UA to evaluate the therapeutic effects of UA-modified UP-AA-NLC on liver targeting and anti-fibrosis activity in carbon tetrachloride (CCl4)-induced liver fibrosis rat model.

2. Materials and methods

2.1. Chemicals and animals

Asiatic acid (98%) was purchased from Guangxi Institute for Food and Drug Control (Guangxi, China). Glycyrrhetinic acid (IS, >99%) was acquired from Shanghai Chenyi Biological Technology Co., Ltd. (Shanghai, China). β-Glucuronidase (Type B-1, ≥1,000 units/g) was procured from Sigma-Aldrich (St. Louis, MO). PEG2000-SA was purchased from Kasei Kogyo Co., Ltd. (Tokyo, Japan). Ursodeoxycholic acid (99%) was purchased from Aladdin (Shanghai, China). The superoxide dismutase (SOD), malondialdehyde (MDA), and hydroxyproline (HYP) detection assay kits were purchased from Nanjing Jiancheng Biotechnology Institute (Nanjing, China). All chemicals and reagents were of analytical or HPLC grade.

Male Sprague-Dawley (SD) rats (200 ± 20 g) and ICR mice (4–5 weeks) were purchased from Zhejiang Laboratory Animal Center (Hangzhou, China) and maintained at 22 ± 2 °C in a 12-h light/12-h dark cycle. The animal experiments adhered to laboratory animal care principles and were approved by the Institutional Animal Ethical Committee of Zhejiang (China).

2.2. Preparation and characterization of UA-PEG-SA

The chemical reaction scheme for UA-PEG-SA conjugate preparation is illustrated in Figure 1(A). Briefly, the hydroxyl group on UA was reacted with acetic anhydride to form an ester for protection. The resultant acetylated UA was reacted with PEG-SA at room temperature to form esters, catalyzed by DCC and DMAP.

2.2.1. Synthesis of acetylated ursodeoxycholic acid

Ursodeoxycholic acid (15.7 g, 40 mmol), acetic acid (4 mL), and acetic anhydride (120 mL) were added into a round bottom flask, and refluxed at 140 °C by a magnetic stirrer. Samples were collected at varying times, diluted 10 times with dichloromethane, and monitored via TLC (CH2Cl2:CH3OH:CH3COOH = 50:1:0.05). Eight hours later, the solvent was removed by evaporation on a rotary evaporator (Rotavapor R-210, Buchi, Flawil, Switzerland). The crude product was dissolved in dichloromethane, mixed with an equal volume of water, and stirred for 4 h. The dichloromethane layer was removed. Subsequently, an equal amount of water was added and stirred for 4 h. These steps were repeated thrice. Finally, an appropriate amount of anhydrous sodium sulfate was added to the dichloromethane layer, stirred overnight, and filtered. The filtrate was evaporated to dryness on a rotary evaporator. The resultant oily substance was purified on silica gel column (CH3Cl2:CH3OH = 100:1, v/v) and the TLC Rf = 0.28 (CH3Cl2:CH3OH:CH3COOH = 50:1:0.05, color developed with sulfuric acid) was collected.

2.2.2. Synthesis of UA-PEG-SA

Acetylated UA 1.7 g (3.75 mmol) and PEG-SA 7.5 g (3.75 mmol) were weighed into a round bottom flask. Next, 150 mL of toluene was added, and the mixture refluxed until no water droplets appeared in the water separator (125 °C for 5 h, magnetic stirred). The mixture was dried under reduced pressure. After that, DCC (1.5 g), DMAP (0.1 g), and dichloromethane were added and stirred for two days at 25 °C. The filtrate was washed thrice with saturated NaHCO3 and NaCl. An appropriate amount of anhydrous sodium sulfate was added to the dichloromethane layer and soaked overnight. The filtrate was decompressed to remove the solvent and purified further on a silica gel column (CH3Cl2:CH3OH = 25:1, v/v). The single point Rf = 0.68 (CH3Cl2:CH3OH = 10:1) analyzed by TLC was visualized with
sulfuric acid. Finally, UA-PEG-SA was vacuum dried at room temperature and recovered as a waxy solid. The acquired solid was dissolved in DMSO-d6 and analyzed by 1H NMR (AC-80, Bruker Biospin Co., Ettlingen, Germany).

### 2.3. Preparation and characterization of AA-loaded nanostructured lipid carriers

#### 2.3.1. Preparation of P-AA-NLC and up-AA-NLC

The AA-loaded NLC modified with PEG-SA (P-AA-NLC) and UP-PEG-SA (UP-AA-NLC) was prepared using solvent diffusion method (Chen et al., 2020). Briefly, AA, glyceryl monostearate, oleic acid, PEG-SA, or UP-PEG-SA were accurately weighed and dissolved in ethanol (70 °C). Subsequently, the mixture was added into distilled water at the same temperature under a mechanical stirrer at 500 rpm. The organic solvent in the dispersion was removed under reduced pressure at 40 °C. The prepared NLC was centrifuged (at 5000 rpm) for 10 min to remove unwrapped AA (AnkeGL-20G-II, Shanghai, China). Fluorescent NLCs were prepared by DIR and utilized in the in vivo distribution studies.

#### 2.3.2. Experimental design

A Box–Behnken design (BBD) with three factors and three levels was utilized for UP-AA-NLC optimization. Fitting analysis on the test data was achieved with Design Expert 8.0.6 (Stat-Ease, Inc., Minneapolis, MN). According to preliminary results, three independent factors significantly influenced NLC formulation, including AA/lipid (A, 5–30%), UA-PEG-SA/lipid (B, 5–20%), and oleic acid/lipid (C, 10–30%). The four dependent variables included particle size ($Y_1$), zeta potential ($Y_2$), encapsulation efficiency (EE) ($Y_3$), and drug loadings (DLs) ($Y_4$). The factor levels were coded as (−1, 0, and 1) as listed in Table 1. The experimental design and response value results of Box–Behnken are displayed in Table 2. Analysis of variance (ANOVA) was applied to evaluate the significance of each factor by $p$ value ($<.05$) and select the appropriate model. The polynomial equation generated for this experimental design is as follows:

$$Y = b_0 + b_1A + b_2B + b_3C + b_{12}AB + b_{13}AC + b_{23}BC + b_{11}A^2 + b_{22}B^2 + b_{33}C^2$$  (1)

where $Y$ is the dependent variable; $b_0$ is the intercept; $b_1$ to $b_{33}$ are the regression coefficients; A, B, and C are the factors being investigated.

#### 2.3.3. Characterization of up-AA-NLC

The mean particle size, zeta potential, and polydispersity index (PI) of NLCs were detected by Zetasizer Nano ZS90 (Malvern, Malvern, UK) at a constant temperature of 25 °C. Freshly prepared samples were dispersed in ultrafiltration

![Figure 1. Synthesis scheme (A) and 1H-NMR spectra (B) of UA-PEG-SA conjugate. (a) Acetylated ursodeoxycholic acid; (b) UA-PEG-SA conjugate.](image)
Table 2. Design and response values of the Box–Behnken test (n = 3).

| Run | Std | A, % | B, % | C, % | Y1, nm | Y2, mV | Y3, % | Y4, % |
|-----|-----|------|------|------|--------|--------|------|------|
| 1   | 12  | 0    | 1    | 1    | 192.3  | –19.2  | 86.72| 11.11 |
| 2   | 5   | –1   | 0    | 0    | 167.1  | –22.9  | 90.30| 3.65  |
| 3   | 3   | –1   | 1    | 0    | 173.9  | –28.0  | 84.55| 3.53  |
| 4   | 14  | 0    | 0    | 0    | 183.2  | –24.9  | 83.63| 10.94 |
| 5   | 2   | 1    | –1   | 0    | 158.8  | –21.7  | 70.50| 15.50 |
| 6   | 7   | –1   | 0    | 1    | 171.5  | –26.6  | 77.57| 3.37  |
| 7   | 15  | 0    | 0    | 0    | 183.2  | –24.9  | 83.63| 10.94 |
| 8   | 13  | 0    | 0    | 0    | 183.2  | –24.9  | 83.63| 10.94 |
| 9   | 17  | 0    | 0    | 0    | 183.2  | –24.9  | 83.63| 10.94 |
| 10  | 6   | 1    | –1   | –1  | 179.9  | –19.9  | 77.81| 16.25 |
| 11  | 1   | –1   | 1    | 0    | 160.9  | –31.2  | 85.11| 4.20  |
| 12  | 4   | 1    | 1    | 0    | 195.0  | –27.0  | 69.65| 13.94 |
| 13  | 10  | 0    | 1    | –1  | 178.0  | –18.7  | 83.05| 10.42 |
| 14  | 9   | 0    | –1   | –1  | 150.9  | –21.6  | 80.80| 11.62 |
| 15  | 8   | 1    | 0    | 1    | 165.9  | –26.1  | 77.13| 15.54 |
| 16  | 17  | 0    | 0    | 0    | 183.2  | –24.9  | 83.63| 10.94 |
| 17  | 11  | 0    | –1   | 0    | 158.2  | –27.9  | 79.90| 11.45 |

Y1: particle size; nm; Y2: zeta potential, mV; Y3: encapsulation efficiency, %; Y4: drug loadings, %.

The physical stability of UP-AA-NLC was examined by monitoring the size changes at different time points under 4 °C storage conditions. The stability of UP-AA-NLC in serum was also investigated. Freshly prepared UP-AA-NLC was dispersed in 10 mL pH 7.4 PBS (containing 10% fetal bovine serum) and incubated at 37 °C. Samples were collected at a predetermined time to measure the particle sizes.

2.4. In vitro release of AA

In vitro release of AA, P-AA-NLC, and UP-AA-NLC was conducted in pH 7.4 PBS (1% SDS, w/v) by the dialysis bag technology (MWCO: 3500Da, Wuhan Xinsirui Technology Co., Ltd., Wuhan, China). The temperature of the oscillator (HZ-9211KB, HualiDa Laboratory Equipment Company, Jiangsu, China) was set to 37 °C at stirring rate of 100 rpm. An aliquot (1 mL) was collected at scheduled time points and replaced with an equal volume of PBS (pH 7.4). All samples were filtered and analyzed by HPLC as described previously.

To explore the AA release mechanism of NLCs, the in vitro release data were fitted to the Ritger–Peppas model (Ritger & Peppas, 1987), which has high fitness for the nanoparticle release process (Cunha et al., 2020; Wu et al., 2021):

$$\frac{M_t}{M_\infty} = k t^n$$

where $M_t$ and $M_\infty$ denoted the cumulative AA release at time $t$ and infinite time, respectively; the release mechanism was reflected by release exponent $n$; $k$ is the release constant. If $n = 0.45$, the release mechanism corresponded to Fickian’s diffusion; when $0.45 < n < 0.89$, non-Fickian (anomalous) drug diffusion occurs; $n = 0.89$ represents case II transport, and $n > 0.89$ represents super case II transport (Jamwal et al., 2019).

2.5. Cell proliferation experiment

The proliferation of LX-2 cells was evaluated by a cell counting kit-8 (CCK-8; Beyotime, Haimen, China). Briefly, LX-2 cells were seeded into 96-well plates ($6 \times 10^4$ cells/well) and incubated for 12 h. The cells were subsequently incubated with different concentrations of AA or UP-AA-NLC for 24 h (0, 4, 10, and 25 μM). The OD_{570} values of each well were recorded using a SpectraMax iDS microplate reader (Molecular Devices, Sunnyvale, CA). Wells untreated with drugs represented 100% cell viability.

2.6. Quantitative real-time polymerase chain reaction (q-PCR) experiment

LX-2 cells were seeded into 96-well plates ($2 \times 10^5$ cells/well) and pretreated with TGF-beta1 (R&D System, Minneapolis, MN) overnight at 10 ng/mL concentration. This was followed by the addition of different concentrations of AA or UP-AA-NLC for 48 h (0, 4, 10, and 25 μM). Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). RNA concentration was assessed by NanoDrop2000 spectrophotometer (Thermo Scientific, Waltham, MA). The mRNA expression of water and ultrasonically dispersed for 3 min (JY92-2D, Scientz Biotechnology Co. Ltd., Ningbo, China).

The NLC suspension was centrifuged to remove free AA because of the low water solubility of AA. The supernatant (1 mL) was precisely pipetted, diluted to 25 mL with ethanol, and heated for 30 min at 70 °C. Filtered samples were analyzed via HPLC as described previously (Chen et al., 2020).

The HPLC system comprised a binary LC-20AD pump (Shimadzu, Kyoto, Japan), an SPD-20A UV-vis detector (Shimadzu, Kyoto, Japan), and Diamonsil™ C۱۸ column (5 μm, 250 mm × 4.6 mm). The mobile phase was prepared with methanol/acetonitrile (1:1, v/v) and 0.02 mol/L KH₂PO₄ (pH 3.0) at a volume ratio of 80/20. The detection wavelength and the flow rate were set at 210 nm and 1.0 mL/min, respectively. The column temperature was thermostatized at 25 °C. The EE (%) and DLs (%) were calculated according to formulas (2) and (3):

\[
EE(\%) = \frac{\text{amount of drug in NLC}}{\text{total drug added} \times 100\%} \\
DL(\%) = \frac{\text{amount of drug in NLC}}{\text{weight of NLC} \times 100\%}
\]
Actin, α-smooth muscle actin (α-SMA), fibronectin 1 (FN1), and collagen type I alpha 1 chain (Col I α1) was quantified via SYBR-based quantitative PCR analysis (Hieff® qPCR SYBR® Green Master Mix, Yeasen Biotech Co., Ltd., Shanghai, China) on a programmed My Cycler (BIO-RAD, Feldkirchen, Germany). Thermocycling conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Melting curve conditions were 95°C 40s, and the temperature was dropped to 60°C in 1 min. The sequences of primers were used as follows: actin (human) forward: 5'-CTCATCTCGCTGCTGT-3', reverse: 5'-GGTTCACCCCTACCCTAC-3'; α-SMA (human) forward: 5'-TTCATGCTACCAGCCATGTA-3', reverse: 5'-GCAAGGCATGACCTCAGTACG-3'; FN1 (human) forward: 5'-ATCACCCCTACCAACTTACCC-3', reverse: 5'-TCCCCTCAGAACATCAAAAC-3'; Col I α1 (human) forward: 5'-ACCTGAGACCCTGCTGTGA-3', reverse: 5'-GAATCCATCGGTCATGCTCTGTC-3'. The data were analyzed using the comparative $2^{-\Delta\Delta Ct}$ method. The PCR test was performed in triplicate.

2.7. In vivo near-infrared fluorescence imaging

Free DIR, DIR-labeled P-AA-NLC, and UP-AA-NLC were used to study the in vivo targeting efficacy after modification. Briefly, 15 ICR mice were divided randomly into three groups, and orally administered with different formulations at a 20 mg DIR/kg dose. The mice were anesthetized at predefined time points. The fluorescence of the formulations was visualized by a living imaging system (Clairvivo OPT, Shimadzu, Kyoto, Japan) at excitation and emission wavelengths of 748 nm and 780 nm, respectively. The exposure time was 30 seconds per cube. Finally, mice were sacrificed, and their hearts, livers, spleens, lungs, and kidneys were resected. NIR fluorescence signal intensity of different tissues was measured to examine the biological distribution of NLCs.

2.8. Tissue distribution in rats

A highly sensitive HPLC method was developed to detect the concentration of drugs in the major organs after oral administration of AA or UP-AA-NLC. The HPLC system contained a binary pumps, UV-vis detector (Shimadzu, Kyoto, Japan), a C8 column (5 μm, 150 mm × 4.6 mm). The HPLC mobile phase solvent A contained distilled water, and solvent B was methanol-acetonitrile (1:1). The gradient elution procedure was as follows: 0–10 min, 25% A, 75% B; 10–25 min, 11% A, 89% B → 25% A, 75% B; 25–27 min, 25% A, 75% B. The UV wavelength, the flow rate, and column temperature were set at 248 nm, 1.0 mL/min, and 25°C, respectively.

In vivo, near-infrared fluorescence imaging results showed that UP-AA-NLC reached peak concentration at 24 h. In this view, the concentration of AA, P-AA-NLC, and UP-AA-NLC, at 64 mg/kg dosage, was determined in ICR mice at 24 h. The heart, liver, spleen, lung, and kidney were excised and homogenized in normal saline. Subsequently, β-glucuronidase was added and hydrolyzed at 37°C for 24 h. Glycyrhetinic acid served as the internal standard. The mixture was extracted with methyl tert-butyl ether and centrifuged. The supernatant was collected, dried with nitrogen, and derivatized following a previously described protocol (Zheng & Wang, 2009). The concentration of AA in each organ was quantified under the above HPLC conditions.

2.9. Animal model of CCl4-induced liver fibrosis and experimental design

Seventy SD rats who underwent adaptive feeding for a week were divided randomly into seven groups (n = 10 for each group) including: (1) normal group, (2) liver fibrosis group, (3) colchicine group (0.1 mg/kg), (4) free AA group (32 mg/kg), and (5–7) UP-AA-NLC groups (16 mg/kg, 32 mg/kg, and 64 mg/kg, respectively). Except for the normal group, rats were intraperitoneally injected with 20% CCl4 oil solution (2 mL/kg, twice a week) for 6 weeks to induce liver fibrosis. Rats in groups 3 and 4 were orally administered with colchicine (0.1 mg/kg) or AA (32 mg/kg) daily for six consecutive weeks. Rats in groups 5, 6, and 7 were administered orally with different concentrations of UP-AA-NLC. The body weight was monitored weekly for all rats. At the end of the experiment, the rats were sacrificed, and blood samples were collected to analyze the liver function and fibrosis indicators.

Histological analysis: Liver tissue sections were stained with hematoxylin/eosin (H&E) and examined under an optical microscope (microscope: Nikon Eclipse CI; imaging system: Nikon Digital Sight DS-F12, Tokyo, Japan). The score of liver fibrosis was calculated based on the Metavir scoring system (Bedossa & Poynard, 1996; Liu et al., 2013): grade S0: represented normal liver tissue without fibrosis; grade S1: represented a small number of collagen fibers extending in the portal area or around the central vein, with a relatively intact liver lobule structure; grade S2: represented collagen fibers extending outwards, without formation of pseudolobules; grade S3: represented formed pseudolobules, liver lobule structure disorder, surrounded by fibrous wrapping; grade S4: represented damaged liver structure, diffuse fibrosis, and pseudoglomerulus filled with large and proliferated fibrous tissue. Liver areas with collagen fibrosis were identified by Masson’s trichrome staining. The percentage of blue collagen fibers was determined via the Image Pro-plus 6.0 Software and calculated with formula (5) shown below:

$$\text{The collagen fibers area (\%) = } \frac{\text{blue collagen fibers area}}{\text{whole tissue area}} \times 100\%$$

Biochemical analysis: The levels of AST, ALB, and ALT in serum samples were assessed by a serum biochemical analyzer (BA-88A, Mindray, Shenzhen, China). The levels of SOD, MDA, and Hyp in liver tissues and serum were quantified following instructions on the kit.
2.10. Statistical analysis

Data are presented as the mean ± standard deviation. Groups were compared by the paired-sample t-test and two-way ANOVA. All statistical analyses were performed using GraphPad Prism 8 (La Jolla, CA). Differences in p value *<.05, **<.01, and ***<.001 were considered statistically significant.

3. Results and discussion

3.1. Synthesis of UA-PEG-SA

Figure 1(B) shows the spectra of the structures of intermediate and final products verified by 1H NMR. The signals at δ 4.54–4.64 ppm in Figure 1(B) (a) were attributed to the hydrogen attached to the acetoxy group of UA. No signal peaks were observed between δ 3.87 and 4.45 (the two hydroxyl groups of UA) (Zhang et al., 2019), demonstrating the acetylation of the carboxyl group on UA. The carboxyl active hydrogen of acetyl ursodeoxycholic acid (Figure 1(B) (a)) was δ 11.96 ppm; however, the peak disappeared (Figure 1(B) (b)), indicating complete esterification of the carboxyl group on UA. Additionally, two strong hydrogen signal peaks occurred at δ 3.51 and 1.23 ppm (hydrogen of polyethylene glycol and stearic acid, respectively (Figure 1(B) (b)); however, no other active hydrogen signals were reported, which demonstrate successful esterification of the target product UA-PEG-SA.

Table 3. Statistical ANOVA results of the models for the four responses.

| Response                  | Models  | Std.Dev. | R      | F Value | p Value | Prob > F |
|---------------------------|---------|----------|--------|---------|---------|----------|
| Y1 (particle size)        | Linear  | 8.42     | 0.7990 | 7.65    | .0034   |          |
|                           | 2FI     | 8.31     | 0.8339 | 4.49    | .0184   |          |
|                           | Quadratic| 4.74     | 0.9687 | 11.84   | .0018   |          |
| Y2 (zeta potential)       | Linear  | 2.96     | 0.6190 | 2.69    | .0894   |          |
|                           | 2FI     | 2.93     | 0.7316 | 1.92    | .1728   |          |
|                           | Quadratic| 2.10     | 0.9127 | 3.88    | .0438   |          |
| Y3 (encapsulation efficiency) | Linear | 4.09     | 0.7293 | 4.92    | .0168   |          |
|                           | 2FI     | 4.19     | 0.7884 | 2.74    | .0769   |          |
|                           | Quadratic| 3.40     | 0.9087 | 3.68    | .0497   |          |
| Y4 (drug loadings)        | Linear  | 0.98     | 0.9780 | 95.24   | <.0001  |          |
|                           | 2FI     | 1.09     | 0.9788 | 38.01   | <.0001  |          |
|                           | Quadratic| 0.47     | 0.9973 | 145.14  | <.0001  |          |

3.2. Optimization of up-AA-NLC and response surface analysis

A three-factor, three-level BBD was employed to optimize UP-AA-NLC. The independent variables and observed responses for each of the 17 runs are listed in Table 2. First-order, second-order, and quadratic models were fitted simultaneously using the Design-Expert software. The comparative values, including R, Std. Dev. (SD), F-value, and p values are shown in Table 3. The statistical data showed that the best-fitting model was quadratic, with the lowest SD value and the highest R value. The quadratic equations and 3D response surface plots were generated for each response. Of note, a positive sign in front of a factor in a regression equation indicates that the response is directly proportional to the factor (Narendar & Karthik, 2017). Accordingly, all the three independent variables had interactive effects on zeta potential, particle size, EE, and DL.

According to the factorial design, the mean particle size of NPs fluctuated slightly from 150.9 ± 10.7 nm to 195.0 ± 2.9 nm. 3D response surface plots were created as in Figure 2(A). The PEG/lipid ratio was the primary determining factor of the particle size, and it increased in proportion to the particle size. This could be explained by the change in the spatial structure of the NLC after PEG modification, including the formation of a hydrophilic barrier (Wang et al., 2015). The regression equation for particle size and factors is indicated as:

\[
Y_1 = 183.20 + 3.28A + 13.80B + 1.50C + 5.80AB - 4.60AC + 1.75BC - 4.90A^2 - 6.15B^2 - 7.20C^2
\]

Response surface plots in Figure 2(B) demonstrate how independent variables influence the zeta potential of NPs. The absolute value of zeta potential is inversely proportional to the PEG ratio. To explain this relationship, the PEG chains alter the surface hydrophilicity and reduce the surface charge; the PEGylated NLC alters surface properties, including zeta potential (Liu et al., 2015). Moreover, as the OA ratio increases, the absolute value of the potential increases slightly and then decreases. It is suggested that the carboxyl groups of OA and the accumulation of excessive carboxyl groups may reduce negative potential. The regression equation is as follows:

![Figure 2. Characterization of UP-AA-NLC. The size (A) and zeta potential (B) distribution of UP-AA-NLC. (C) TEM photograph of UP-AA-NLC.](2539)
\[ Y_2 = -24.90 + 1.75A + 1.198 - 2.09C - 2.13AB - 0.63AC + 1.458C - 2.05A^2 - 0.025B^2 + 3.07C^2 \]

As demonstrated in Figure 2(C,D), EE is negatively correlated with AA, implying that an increase in AA dosage drastically decreases EE. On the contrary, DL and AA are positively correlated. The change in the ratio of PEG and OA slightly impacts EE and DL. The regression equations are as follows:

\[ Y_3 = 83.63 - 5.30A - 0.968 - 1.33C - 0.073AB + 3.01AC + 1.148C - 4.05A^2 - 2.13B^2 + 1.12C^2 \]
\[ Y_4 = 10.94 + 5.81A - 0.478 - 0.059C - 0.22AB - 0.11AC + 0.218C - 1.55A^2 - 0.100B^2 + 0.31C^2 \]

### 3.3. Formulation optimization for the up-AA-NLC and model validation

Based on the BBD, the optimum percentages were 17% of AA/lipid, 5% of UA-PEG-SA/lipid, and 28% of OA/lipid. Table 4 shows the predicted and experimental zeta potential, particle size, EE, and DL. The absolute value of the deviation between the predicted and experimental values was less than 5%, demonstrating strong predictability of the established model and high reproducibility of the selected formulation.

### 3.4. Characterization of the UP-AA-NLC

The average particle size of the optimized UP-AA-NLC was 159.7 ± 4.9 nm and a PI of 0.240 ± 0.015, indicating a relatively narrow particle size distribution and uniform nanoparticle size (Figure 3(A)). Zeta potential represents the degree of repulsion between adjacent and similarly charged particles in a dispersion. A greater absolute value, implies a stronger ability to resist particle agglomeration and greater stability of the dispersion. In the present study, UP-AA-NLC exhibited a negative surface charge (−27.7 ± 1.7 mV), demonstrating high stability. The percentage values of EE and DL in UP-AA-NLC were 77.44 ± 0.69% and 10.53 ± 0.10%, respectively (Table 4). The TEM images of the optimized UP-AA-NLC showed that the nanoparticles were mainly spherical (Figure 3(C)) with similar sizes to those detected by Zetasizer.

The DSC thermograms of AA powder (A), ingredient mixtures (B), physical mixtures (C), UP-AA-NLC (D), and P-AA-NLC (E) are shown in Figure 4. Of note, AA exhibited a sharp endothermic peak at 233.6 °C. The ingredient mixtures had two melting peaks at 50.2 °C and 71.8 °C. All the peaks were observed in the physical mixtures but with a slight shift. However, the AA peak disappeared from the thermograms of the NLCs (UP-AA-NLC and P-AA-NLC), indicating the conversion of the drug from a crystalline form to an amorphous state.

To evaluate the microstructure changes of AA in NLCs, XRD was used and the spectra of AA powder (A), ingredients mixtures (B), physical mixtures (C), UP-AA-NLC (D), and P-AA-NLC (E) are displayed in Figure 5. The XRD spectrum of AA powder exhibited sharp peaks at 2\(\theta\) scattering angles from 10° to 16°, indicating AA was crystallized. Both ingredient and physical mixtures had intense diffraction peaks at 2\(\theta\) from 19° to 25°, demonstrating that the lipids were in a stable crystalline state. However, the XRD spectrum of UP-AA-NLC and P-AA-NLC exhibited weak and broad diffraction peaks.

| Response | Predicted value | Experimental value | Deviation (%) |
|----------|-----------------|--------------------|---------------|
| \(Y_1\)  | 158.1           | 159.7 ± 4.9        | -1.0          |
| \(Y_2\)  | -27.0           | -27.7 ± 1.7        | -2.6          |
| \(Y_3\)  | 79.35           | 77.44 ± 0.69       | 2.4           |
| \(Y_4\)  | 11.05           | 10.53 ± 0.10       | 4.7           |

*Mean ± SD, n = 3.

Figure 3. DSC image of (A) AA powder, (B) Ingredients mixtures, (C) Physical mixtures, (D) UP-AA-NLC, (E) P-AA-NLC.

Figure 4. X-ray Diffraction Pattern of (A) AA powder, (B) Ingredients mixtures, (C) Physical mixtures, (D) UP-AA-NLC, (E) P-AA-NLC.
peaks, which indicated partial loss of crystallinity and suggested that AA was in an amorphous state in NLCs.

The average particle size of UP-AA-NLC remained stable at 4°C for over 12 days (Figure 6(A)). Further evaluation of the stability of UP-AA-NLC was conducted under simulated physiological circulation. Results showed that the change in the size of UP-AA-NLC at 37°C was not significant, indicating that NLC remained stable in blood in vivo within 12 h.

3.5. Drug release in vitro

The release patterns of AA, P-AA-NLC, and UP-AA-NLC are illustrated in Figure 7. The AA solution released about 90%
within 24 h, while UP-AA-NLC was slower and released 41%, indicating that drug release from the lipid matrix was blocked. The discrepancy in release patterns between AA and NLCs may be attributed to the entrapment of drug molecules in the insoluble lipid matrix. It is noteworthy that the solid shell in the NLCs could protect and immobilize AA in the core of the NLC. Similar drug release behavior was reported for P-AA-NLC and UP-AA-NLC, but neither showed explosive release in the initial stage. This phenomenon demonstrates that the unencapsulated drug was not attached to the surface of the particle.

To clarify the mechanism of AA release from NLCs, the release index \( n \) was calculated according to Equation (4). The \( n \) values of P-AA-NLC and UP-AA-NLC were 0.53 (\( R = 0.982 \)) and 0.52 (\( R = 0.972 \)), respectively, demonstrating that the release mechanism of P-AA-NLC and UP-AA-NLC both followed an abnormal transmission mechanism. These results indicate the possible involvement of diffusion and lipid erosion in controlling the drug release rate of the lipid core and surfactant interface membrane (Wu et al., 2021).

### 3.6. Effects of AA or up-AA-NLC on LX-2 cell proliferation and activation

A concentration-dependent phenomenon was observed in the cell viability of AA, greater than 91% in concentrations ranging between 4 and 25 \( \mu \text{M} \) (Figure 8(A)). However, the cell proliferation rate of the UP-AA-NLC group decreased to 87.24% following an increase in concentration to 25 \( \mu \text{M} \). These data indicate an inhibitory effect of UP-AA-NLC against HSCs and the suppression of the proliferation of LX-2 cells by high-dose NLCs.

To ascertain whether AA and NLCs inhibited the activation of HSCs, LX-2 cells were treated with AA or UP-AA-NLC. Next, the expression of \( \alpha \)-SMA, FN1, and Col I \( \alpha 1 \) was measured by q-PCR. The analysis demonstrated that AA and NLCs exert potential antifibrotic effects by decreasing HSC proliferation and inhibiting HSC myofibroblast differentiation. These results were confirmed by the decreased expression of \( \alpha \)-SMA, FN1, and Col I \( \alpha 1 \) (Figure 8(B)). Compared to the AA group, incubation with UP-AA-NLC significantly downregulated the mRNA levels of \( \alpha \)-SMA, FN1, and ColI1A1 in LX-2 cells treated with TGF-\( \beta 1 \) (Figure 8(B)). The findings suggest that UP-AA-NLC further attenuated TGF-\( \beta 1 \)-induced proliferation and activation.

### 3.7. Biodistribution and in vivo imaging

Figure 9(A) shows the real-time distribution of DIR fluorescence in living mice after oral administration of DIR solution, DIR-loaded AA-NLC, and DIR-loaded UP-AA-NLC. Results showed DIR accumulation in the liver, and weakened fluorescence intensity after 24 h, indicating that DIR was metabolized. The visible fluorescence accumulation of the AA-NLC group increased gradually in the liver after 30 min and peaked at 12 h (Figure 9(B)). Results demonstrated that nanoparticles potentially prolong drug retention duration in vivo and improve oral absorption. The concentration of DIR fluorescence in the liver increased rapidly after modification with UA, in which the first absorption peak was observed at 2 h. Subsequently, the concentration decreased slowly and reached the second peak at 24 h; however, the fluorescence value was still detectable at 48 h. The two peaks of UP-AA-NLC may be related to the involvement of UA in enterohepatic circulation, which successively increases the circulation time of the drug in the body. Ursodeoxycholic acid is a type of bile salt transporter ligand that binds to the ASBT receptor of intestinal epithelial cells. Research shows that AA can cause a significant increase in drug concentrations in the body after oral administration (Sievanen, 2007). Pictures shown in Figure 8(B) are based on a semi-quantitative analysis of the ROI in the liver performed using the built-in software, which also confirms the preceding conclusions. The 48-h \( \text{ex vivo} \) image of resected organs (Figure 9(C)) provided evidence that the DIR-loaded UP-AA-NLC group had a greater fluorescence signal in the liver than the DIR solution and DIR-loaded AA-NLC groups. This could be because the specific binding of UA to the NTCP receptor of hepatocytes allows for selective accumulation of the drug in the liver and long-term retention (Sievanen, 2007).

### 3.8. Tissue distribution study

There was no evidence of endogenous interference in detecting of AA (10.8 min) or IS (19.4 min) in the heart, liver, spleen, lung, or kidney homogenates. Acceptable linear
relationships were found in all the tissues over the AA concentration ranging from 0.1 to 8 μg/mL. The calibration curves were as indicated: \( y = 0.1258x - 0.0135 \) (\( r = 0.9992 \), heart), \( y = 0.1204x - 0.0137 \) (\( r = 0.9991 \), liver), \( y = 0.1332x - 0.017 \) (\( r = 0.9996 \), spleen), \( y = 0.1238x - 0.008 \) (\( r = 0.9997 \), lung), and \( y = 0.1146x - 0.005 \) (\( r = 0.9993 \), kidney). The lowest concentration on the standard curve (denoted as LLOQ) was 0.1 μg/mL, and the RSD of all tissue homogenates was less than 8%. These results demonstrated the method was sufficiently sensitive to meet the in vivo biological analysis requirements of AA. The intra- and inter-day precision and accuracy of QC samples at 0.5, 2, and 4 μg/mL are summarized in Table 5. The recoveries of the three levels in all tissue homogenates were above 70%, indicating that the extraction method was acceptable. The stability of AA in tissues was tested on 5, 15, and 30 days at concentrations of 0.5, 2, and 4 μg/mL, respectively, under storage at −20 °C. The samples were analyzed and compared to freshly prepared QC samples. The RSD values of AA concentration in organs were less than 6%, demonstrating that

Table 5. Precision, accuracy, and recovery for assay of AA in various tissue homogenates (mean ± SD, \( n = 5 \)).

| Samples | Conc. (μg/mL) | Extraction recovery (%) | Accuracy (%) | Relative standard deviation (%) |
|---------|--------------|-------------------------|--------------|-------------------------------|
| Heart   | 0.5, 2, 4    | 77.19 ± 7.51, 74.54 ± 6.93, 76.24 ± 2.03 | 100.92 ± 6.24, 99.95 ± 4.31, 97.55 ± 9.71 | 5.13, 4.82, 4.7 |
| Liver   | 0.5, 2, 4    | 75.62 ± 5.45, 71.17 ± 3.44, 76.34 ± 2.03 | 101.52 ± 3.65, 101.89 ± 7.06, 97.55 ± 9.71 | 4.82, 6.36, 6.36 |
| Spleen  | 0.5, 2, 4    | 77.26 ± 4.64, 73.08 ± 5.48, 72.24 ± 3.77 | 95.80 ± 4.03, 101.39 ± 5.15, 99.00 ± 3.17 | 5.71, 3.22, 2.20 |
| Lung    | 0.5, 2, 4    | 74.25 ± 1.89, 74.61 ± 6.97, 76.82 ± 7.70 | 100.25 ± 4.13, 99.85 ± 6.24, 103.47 ± 2.63 | 4.30, 2.72, 2.43 |
| Kidney  | 0.5, 2, 4    | 74.17 ± 5.22, 73.88 ± 4.01, 73.34 ± 5.29 | 101.27 ± 4.60, 96.44 ± 4.02, 102.82 ± 2.87 | 7.44, 3.82, 4.59 |

Figure 9. In vivo imaging of AA, P-AA-NLC and UP-AA-NLC biodistribution in rats. (A) Whole body imaging from 0 to 48 h. (B) The fluorescence intensity of the liver sites. (C) The imaging of the dissected major organs. *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \).
AA was stable in the heart, liver, spleen, lung, and kidney homogenates.

The presently established method was applied to investigate the distribution of AA and NLCs in tissues in rats. Results for drug concentrations in the heart, liver, spleen, lung, and kidney at 24 h following oral administration of AA, P-AA-NLC, and UP-ALC, are shown in Figure 10. Of note, AA was mainly distributed in the liver, heart, and kidney, supported by previously reported distribution characteristics (Yin et al., 2012). Also, NLC potentially improves the absorption of AA. The organ concentration increased with further modification of UA. Among these, the concentration in the liver increased the most, by 6.2 times that of the AA group and 1.9 times that of the P-AA-NLC group; these results largely concurred with the conclusions of in vivo imaging.

### 3.9. Anti-liver fibrosis therapy in vivo

Pharmacodynamics studies were performed in the rat model of CCl₄-induced liver fibrosis. After six weeks of CCl₄ administration, weight gain in the model group (liver fibrosis group) was slow, but similar to that of normal rats in the other groups (Figure 11(A)). The organ coefficients of each group are shown in Figure 10(B). Compared to the normal group, the liver coefficient of the model group was elevated drastically ($p<.001$), but later decreased post AA administration. The results suggest that AA has a protective effect on liver fibrosis, which is consistent with the conclusion of references (Gao et al., 2006; Tang et al., 2012). The protective effect may be related to the regulation of PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways (Wei et al., 2018). The liver coefficient in colchicine and UP-AA-NLC groups was significantly reduced; however, the difference to the normal group was not significant ($p>.05$).

The H&E staining examination revealed pathological morphological changes in the liver of rats after injection of CCl₄. Compared to the normal liver (Figure 12(A) (a)), liver necrosis in the model group was more severe (Figure 12(A) (b)) due to hyperplasia of collagen fibers, formation of pseudolobules (black arrow), and inflammation (red arrow). Moreover, it can also be seen that there were small bile ducts proliferating in collagen (yellow arrows) and cytoplasmic round fat vesicles (green arrows). Colchicine, as the positive control, effectively protected the liver and repaired the CCl₄-induced damage. Figure 12(A) (d) shows hyperplasia of collagen fibers around the veins with marked extension (black arrow), demonstrating better granules in the liver tissue. Furthermore, the improvement of liver steatosis and fibrotic diaphragm (black arrow) showed the anti-liver fibrosis effect of AA (Figure 12(A) (c)). The liver morphology of the UP-AA-NLC group at low (16 mg/kg), medium (32 mg/kg), and high doses (64 mg/kg) respectively, is shown in Figure 12(A) (e–g). According to the images, the outward extension of collagen fibers became less pronounced as the dose increased. At the dosage of 64 mg/kg, the liver morphology was similar to the normal group. These results suggest that UP-AA-NLC can effectively prevent and reverse CCl₄-induced chronic liver injury.

Excessive ECM deposition is a crucial feature of liver fibrosis, and collagen is a major component of ECM. In the present study, Masson staining detection of collagen expression in rat liver revealed significant collagen accumulation in liver damaged by CCl₄. The collagen fiber area in the model group was over 10% (Figure 12(Bb,C)) but reduced to 2.8% in the colchicine group. The UP-AA-NLC group had significantly less liver fibrosis and less accumulation of collagen fibers, which was comparable to or better than the colchicine...
group. Furthermore, the collagen fiber area of UP-AA-NLC decreased to 32% \((p < .01)\), 21% \((p < .001)\), and 16% \((p < .001)\) of the model group at low, medium, and high concentrations, respectively.

As shown in Figure 12(D), the liver fibrosis scores mainly dominated in grades S4 (70%) and S3 (30%) in the model group and grades S1 (60%) and S2 (40%) in the colchicine treatment group. Compared to the AA group, under the same dose (32 mg/kg), the UP-AA-NLC group had significantly less liver fibrosis, reported in grade S1 (70%). It was reported that P-AA-NLC without UA modification was mainly classified as S2 (50%) at 32 mg/kg (Chen et al., 2020), which also confirmed the protective effect of UA on the liver. Of note, the effect was more pronounced when the dose was increased, and the presence of S0 levels indicated a significant reduction in liver disease. The findings demonstrate that UP-AA-NLC can alleviate CCl4-induced liver fibrosis.

Serum biochemical marker enzymes, viz. AST and ALT levels were increased significantly, and the ALB level was decreased significantly in the model group compared to the normal group (238.92 ± 16.38%, 558.54 ± 72.75%, and 46.58 ± 4.28% of the normal control, \(p < .001\)) (Figure 13(A–C)). These findings indicate that CCl4 successfully induced liver fibrosis. Treatment with UP-AA-NLC reduced liver functional impairment in a dose-dependent manner, with significant effects at doses of 32 and 64 mg/kg. The 64 mg/kg dose group of UP-AA-NLC had better efficacy than the colchicine group. The values of AST, ALT, and ALB were 115.29 ± 7.14%, 157.86 ± 24.37%, and 84.38 ± 3.61% of the normal group, respectively.

The measurement results of anti-oxidant activity parameters are shown in Figure 13(D,E). Compared to the normal group, CCl4 treatment effectuated a significant decrease in SOD and a remarkable increase in MDA \((p < .001)\). Among
these treatments, the UP-AA-NLC 64 mg/kg group exhibited the most significant effect on the elevation of SOD and reduction of MDA. These results provide evidence that UP-AA-NLC can effectively inhibit liver fibrosis by blocking oxidative stress. HYP is a unique amino acid composition of collagen, and its abundance in the liver reflects changes in collagen metabolism (Shkurupii et al., 2014). Herein, treatment with colchicine, AA, and its NLCs drastically lowered HYP levels in the fibrotic liver (Figure 13(F)), indicating that collagen accumulation in the fibrotic liver was decreased. Overall, these data demonstrate that UP-AA-NLCs potentially attenuate CCl4-induced liver fibrogenesis by suppressing collagen expression.

4. Conclusions

UA-modified UP-AA-NLC has been evaluated as a potential oral drug delivery system that potentially promotes liver targeting abilities and antifibrotic therapeutic efficacy. The formulation of nanoparticles was optimized using the BBD design based on the size, zeta potential, DL%, and EE% results. TEM images revealed that the produced NLC was spherical and uniform in size. The slow-release characteristics of NLC indicated uniform encapsulation of AA in the lipid matrix. In vitro, anti-fibrosis activity and proliferation of LX-2 cells showed that UP-AA-NLC significantly promoted TGF-beta1-induced α-SMA, FN1, and Col I α1 expression. In vivo biodistribution studies revealed that UP-AA-NLC exhibited liver-targeting capabilities and potentially improved oral absorption of the drug. Also, UP-AA-NLC significantly reduced CCl4-induced liver fibrosis and functional damage in a dose-dependent manner after oral administration. Findings from this work suggest that AA nanoparticles, modified from UA, are potential drug delivery carriers in liver-targeted therapy and sustained drug release.

Disclosure statement

The authors declare no conflicts of interest.

Funding

We are thankful for the support of the Medical and Health Technology Project of Zhejiang Province, China (2019KY062) and the Special Project of Zhejiang Academy of Medical Sciences.
References

Bedossa P, Poynard T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAIVIR Cooperative Study Group. Hepatology 24:289–93.

Chasseaud LF, Fry BJ, Hawkins DR, et al. (1971). The metabolism of asiatic acid, madecassic acid and asiaticoside in the rat. Drug Res 21: 1379–84.

Chen XX, Zhang YW, Zhao PF, et al. (2020). Preparation and evaluation of PEGylated asiatic acid nanostructured lipid carriers on anti-fibrosis effects. Drug Dev Ind Pharm 46:57–69.

Chen Y, Lu Y, Chen J, et al. (2009). Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm 376:153–60.

Chen ZP, Zhu JB, Chen HX, et al. (2010). Synthesis of a novel polymer bile salts-(polyethylene glycol)2000-bile salts and its application to the liver-selective targeting of liposomal DDB. Drug Dev Ind Pharm 36:657–65.

Cunha S, Costa CP, Loureiro JA, et al. (2020). Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutica 12:599.

Dawson PA. (2011). Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol 201:169–203.

Doane T, Burda C. (2013). Nanoparticle mediated non-covalent drug delivery. Adv Drug Deliv Rev 65:607–21.

Fiorucci S, Antonelli E, Morelli O, et al. (2001). NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 98:8897–902.

Fiorucci S, Antonelline E, Tocchetti P, et al. (2004). Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc Drug Rev 22:135–46.

Gao J, Chen J, Tang XH, et al. (2006). Mechanism underlying mitochondrial protection of asiatic acid against hepatotoxicity in mice. J Pharm Pharmacol 58:227–33.

Jamwal S, Ram B, Ranote S, et al. (2019). New glucose oxidase-immobilized stimuli-responsive dextran nanoparticles for insulin delivery. Int J Biol Macromol 123:968–78.

Liu GJ, Ji Q, Moriyasu F, et al. (2013). Value of contrast-enhanced ultrasound in evaluating perfluorobutane microbubbles for diagnosing liver fibrosis and cirrhosis in rats. Ultrasound Med Biol 39:2158–65.

Liu X, Zhang ZH, Jiang YQ, et al. (2015). Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti- leukemia agent tamibarotene: characterization and evaluation. Drug Deliv 22:223–9.

Mishra B, Patel BB, Tiwari S. (2010). Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6:9–24.

Mi-Sook D, Seung-Hyun J, Hyun-jung K, et al. (2004). Structure-related cytotoxicity and anti-hepatotoxic effect of asiatic acid derivatives in rat hepatic stellate cell-line, HSC-T6. Arch Pharm Res 27:512–7.

Müller RH, Radtke M, Wissing SA. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–8.

Narendar D, Karthik YJ. (2017). Lipid nanoparticles of zepalon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm 43:1205–14.

Pakdeechope T, Bunbupha S, Sukongviriyapan U, et al. (2014). Asiatic acid alleviates hemodynamic and metabolic alterations via restoring eNOS/INOS expression, oxidative stress, and inflammation in diet-induced metabolic syndrome rats. Nutrients 6:355–70.

Paschke R, Kalbitz J, Paetz C, et al. (2003). Cholic acid-carboxylatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboxylatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J Inorg Biochem 94:335–42.

Ritger PL, Peppas NA. (1987). A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release 5:37–42.

Rush WR, Murray GR, Graham DJM. (1993). The comparative steady-state bioavailability of the active ingredients of madecassol. Eur J Drug Metab Pharmacokinet 18:323–6.

Shikhrueva SS, Vaidya R, Sutar S, et al. (2008). Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv 5:324–31.

Shidhaye VA, Kim LB, Potapova OV, et al. (2014). Study of fibrotic complications and hydroxylamine content in mouse liver at different stages of generalized BCG-induced granulomatosis. Bull Exp Biol Med 157:466–9.

Shouval D, Friedman SL. (2014). Focusing on the past, present, and future of hepatology. J Hepatol 61:1196–8.

Sievenan E. (2007). Exploitation of bile acid transport systems in prodrug design. Molecules 12:1859–89.

Tang LX, He RH, Yang G, et al. (2012). Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLOS One 7:e31350.

Wang L, Luo Q, Lin TY, et al. (2015). PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A. Drug Dev Ind Pharm 41:1204–12.

Wei LW, Chen QS, Guo AJ, et al. (2018). Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways. Int Immunopharmacol 60:1–8.

Wu KW, Sweeney C, Duhhipala N, et al. (2021). Primquine loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE): effect of lipid matrix and surfactant on drug entrapment, in vitro release, and ex vivo hemolysis. AAPS PharmSciTech 22:240.

Xiao LX, Zhou YQ, Zhang XL, et al. (2019). Transporter-targeted bile acid–camptothecin conjugate for improved oral absorption. Chem Pharm Bull 67:1082–7.

Ye HL, Zhang JW, Chen XZ, et al. (2019). Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci 242:117175.

Yin MC, Lin MC, Mong MC, et al. (2012). Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice. J Agric Food Chem 60:7697–701.

Zhang L, Schuppian D. (2014). Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. J Hepatol 61:166–8.

Zhang X, Fan DD, Hua XF, et al. (2019). Large-scale production of ursodeoxycholic acid from chenodeoxycholic acid by engineering 7α- and 7β-hydroxysteroid dehydrogenase. Bioprocess Biosyst Eng 42:1537–45.

Zhang Z, Gao F, Jiang S, et al. (2013). Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats. Int J Pharm 452:374–81.

Zheng XC, Wang SH. (2009). Determination of asiatic acid in beagle dog plasma after oral administration of Centella asiatica extract by precol- umn derivatization RP-HPLC. J Chromatogr B Analyst Technol Biomed Life Sci 877:477–81.